Drugs
Therapeutics and drugs enable prevention, stabilization, and definitive treatment across military medicine: antimicrobials for battlefield infections and AMR mitigation, hemostatic agents and analgesics for hemorrhage and pain control, neuroprotectants for TBI, antitoxins and antivirals for biothreats, and optimized dosing/formulations for austere and prolonged-field care.
Technical Challenges
Rapid infection control in the presence of antimicrobial resistance and biofilm-associated wound infections.
Effective hemorrhage control and analgesia with limited supplies and delayed evacuation.
Stability, storage, and cold-chain dependence for biologics and antitoxins in austere environments.
Limited point-of-care pharmacokinetic/therapeutic drug monitoring to guide dosing in variable physiology (shock, burns, hypothermia).
Emerging Opportunities
Long-acting, temperature-stable formulations for prophylaxis and acute care to reduce resupply burden.
Rapidly deployable antitoxins, antivirals, and broad-spectrum antimicrobials for emergent biothreats.
Field-capable assays and decision support to personalize dosing during prolonged or distributed care.
Drugs and adjuncts specifically tailored to blast polytrauma, TBI, and multiorgan dysfunction encountered in combat.
Current and Emerging Technologies in Drugs
AI-driven discovery and drug repurposing
Machine learning and in silico screening accelerate identification of candidate therapeutics and repurposed drugs for infections, neuroprotection, and hemostasis, shortening transition from bench to field-ready studies.
Long-acting and temperature-stable formulations
Injectable depot formulations, transdermal systems, and stabilizing excipients extend duration and remove cold-chain constraints for prophylactics, antimicrobials, and analgesics.
Novel antimicrobials and anti-biofilm agents
New classes, bacteriophage therapies, antimicrobial peptides, and biofilm-disrupting adjuncts target resistant wound and device-associated infections common in combat casualties.
On-demand biologics and cell-free manufacturing
Portable platforms for rapid synthesis of antitoxins, monoclonal antibodies, and personalized biologics reduce dependence on central production during outbreaks or supply disruption.
Point-of-care pharmacokinetics and therapeutic drug monitoring
Rapid assays and decision-support tools enable individualized dosing in shock, burn, and hypothermia to avoid under- or overdosing in prolonged-field-care scenarios.
Advanced delivery systems
Novel routes (inhaled, intranasal, microneedle patches, targeted nanoparticles) improve rapid administration, absorption, and triage-level care when IV access is limited.
Importance to Military Medicine
Improve survival from combat injury
Hemostatic agents, analgesics, antimicrobials and resuscitative drugs are life-saving interventions during the initial window after trauma.
Enable prolonged and distributed care
Stable, long-acting drugs and field-capable dosing guidance extend effective care when evacuation is delayed or infrastructure is limited.
Counter biological threats and maintain readiness
Rapid therapeutics for emerging pathogens, antitoxins, and mitigations for AMR protect force health and mission continuity.
Optimize physiological performance and recovery
Neuroprotective agents, rekindled wound-healing therapeutics, and pharmacologic performance aids support return-to-duty and long-term functional outcomes.
Alignment with the MTEC Mission
MTEC accelerates transition of drug candidates and delivery technologies that address DoD priorities—combat casualty care, infectious-disease resilience, prolonged-field-care solutions, and readiness—by connecting military needs, academic science, industry scale-up, and rapid evaluation pathways.
Dual-Use (Military + Civilian) Applications
Dual-use therapeutics benefit both Warfighters and civilians: battlefield antimicrobials inform hospital AMR strategies; long-acting prophylactics support public-health mass prophylaxis.
Portable biologic production and rapid antitoxin platforms have clear civilian utility during outbreaks and in remote health systems.
Point-of-care drug monitoring and dosing decision-support reduce medication errors in both austere military settings and resource-limited civilian hospitals.
Advanced delivery technologies (microneedles, aerosols) expand access to emergency therapeutics for civilians and deployed forces alike.
Explore MTEC Members with Drugs Capabilities
MTEC members — spanning biotech, pharma, academic translational labs, and military clinical research centers — bring complementary strengths: rapid R&D, GMP manufacturing scale-up, regulatory strategy, and field evaluation pathways. Explore member profiles to identify partners for therapeutic discovery, formulation engineering, on-site biologic production, and clinical validation.
124 Members with Drugs capabilities.
The University of Texas System is a leading public university system in the United States, dedicated to improving lives through education, health care, and research. With over 256,000 students enrolled across 14 institutions, the UT System is committed to providing affordable access to higher education and producing a skilled workforce to drive Texas's economy.
Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.
Nuclera develops automated benchtop platforms and integrated systems for rapid protein expression, optimization, and purification, utilizing cell-free synthesis, digital microfluidics, and software-driven workflows. Their technology enables miniaturized and scalable protein prototyping—including challenging targets such as membrane proteins—directly at the lab bench. Nuclera serves academic and industrial researchers, focusing on reducing turnaround time for functional protein access and streamlining screening and production. The company has secured significant funding to enable broad commercialization, expanded their leadership team to support scale-up, and continues to drive advancements in drug discovery, proteomics, and experimental automation.
FiteBac Technology/FiteBac Pharma's K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction. FiteBac Technology innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21.
STAT Therapeutics is focused on developing a drug- device combination for easy, rapid administration of intramuscular, life-saving medications by users in any setting, aiming to improve access and usability for acute emergency treatments such as pain, anaphylaxis, and seizures.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant and difficult-to-treat bacterial infections. With a focus on addressing the global antibiotic resistance crisis, Armata leverages its proprietary bacteriophage-based technology to develop high-impact, best-in-class phage therapeutics. The company operates from a 56,000 square foot facility in Los Angeles, California, equipped for phage product development from bench to clinic. Armata's team of microbiologists and scientists work on discovering natural phages and enhancing them through synthetic biology and engineering to create tailored drug products for clinical trials.
The University of Texas at San Antonio (UTSA) is dedicated to the advancement of knowledge through research, teaching, and community engagement. As a premier public research university, UTSA embraces multicultural traditions and serves as a catalyst for socioeconomic development, providing access to educational excellence and preparing citizen leaders for the global environment.
Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.
Seek Labs is a biotechnology company headquartered in Salt Lake City, Utah, dedicated to advancing scientific discovery and delivering universal healthcare solutions. The company specializes in next-generation point-of-care molecular diagnostics and programmable CRISPR-based therapeutics, aiming to bridge the gap between disease outbreak and intervention. Powered by its proprietary AI discovery engine, BioSeeker™, Seek Labs is building a modular, full-stack system that enables rapid response to emerging pathogens, scalable precision treatments, and accessible diagnostics. The company is committed to global health innovation, sustainability, and community engagement, and is a proud member of Utah's BioHive life sciences ecosystem. Seek Labs' mission is to empower individuals with healthcare solutions tailored to their specific needs, revolutionizing the detection and treatment of diseases for both human and animal health.
The Institute for Integrative & Innovative Research (I3R) at the University of Arkansas is dedicated to pioneering solutions to complex societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I3R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.
UTMB is dedicated to supporting research, education, and scholarly endeavors, with a focus on creating the future of healthcare through innovative research and community engagement.
Action Medical Technologies is a pharmaceutical and medical device company focused on developing innovative solutions that integrate medications with advanced devices and injector systems to improve patient outcomes, particularly in austere prehospital environments.
Vindhya Data Science is a women-owned small business headquartered in North Carolina, USA, with a presence in RTP and Boston. We specialize in bioinformatics, genomics, artificial intelligence, and data engineering, cheminformatics, evidence-based medicine, epidemiology and related disciplines. Vindhya partners with federal government agencies, leading academic medical centers, and pharma/biotech organizations to transform large datasets into informed decisions using advanced data science technologies. With over 100 years of combined experience, 150+ publications, and 73+ successful projects, Vindhya is committed to delivering impactful solutions in the life sciences sector.
The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.
Memsel is a biotechnology research and development company dedicated to enhancing health and combatting infections through advanced phage therapies and targeted delivery systems. The company aims to transform healthcare solutions across human, animal, and plant domains, addressing critical health challenges and antibiotic resistance.
Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.

Safi Biotherapeutics
Next-Generation Manufactured Red Blood Cells for Extended Battlefield Blood Supply: Safi Biotherapeutics
Safi Biotherapeutics is developing manufactured red blood cells (mRBCs) with extended shelf life to improve battlefield transfusion readiness and emergency trauma care.
Non-Invasive Glymphatic (GF) Monitoring and Recovery Optimization for Warfighter Cognitive Readiness
Applied Cognition is developing non-invasive glymphatic monitoring and recovery technologies to enhance warfighter cognitive readiness, resilience, and sleep recovery.
Moberg Analytics
Moberg Analytics – Advanced Brain Monitoring & Critical Care Informatic
Moberg’s platform unifies brain monitoring data for faster, precise treatment of severe brain injuries in military and civilian care.
University of California San Francisco
TemPredict: AI-Driven Wearable Monitoring for Early Illness Detection and Warfighter Readiness
TemPredict: AI wearables detect early illness and health risks to support warfighter readiness.